on behalf of the STOP HIV/AIDS Study Group Objective: The benefits of HAART rely on continuous lifelong treatment retention. We used linked population-level health administrative data to characterize durations of HAART retention and nonretention.
Introduction
Modern HAART has transformed the HIV epidemic in two profound ways [1]: First, at an individual level, persons living with HIV (PLHIV) today are living longer, healthier lives [2, 3] . Second, at a population level, it has been established that the expansion of HAART coverage can lead to a population-level reduction in HIV incidence [4] [5] [6] [7] . The extent of these benefits rely on the continuous lifelong use of HAART, as treatment interruptions have been associated with inferior patient outcomes, increased risk of HIV transmission, and emergence of antiretroviral drug resistance [8] [9] [10] . Structured treatment interruptions were once applied in clinical practice but have been discontinued as of 2005 following evidence-based recommendations discouraging this practice [11] . However, unstructured interruptions and poor or intermittent retention in HAART remain common [12] [13] [14] [15] . It is therefore of vital interest to those engaged in the care of PLHIV to monitor lifelong retention on HAART [16] .
The cascade of HIV care is a well established monitoring tool that measures retention in care and highlights attrition along the HIV care continuum from HIV infection to diagnosis, linkage to HIV care (often defined as the first HIV-related physician visit or diagnostic test), retention in HIV care (regular HIV-related care), to HAART retention and the ultimate goal of virologic suppression [17, 18] . Attrition or 'leakage' at different stages along the cascade is heterogeneous, composed of individuals never accessing a given level of care and those disengaged from regular care. The latter itself is a heterogeneous group comprised of those dropping out of treatment for the first time, those with multiple treatment discontinuations, as well as those lost to HIV care entirely (i.e. discontinued regular physician follow-up and diagnostic testing). The sometimes cyclical process of engagement, disengagement, and reengagement in HIV care has been referred to as cascade 'churn', and has been cited as a crucial component of HIV monitoring [19] [20] [21] [22] . HAART persistence or sustained engagement (as opposed to adherence, which measures the number of prescribed doses of HAART that were ingested) [23, 24] is of particular interest as the ultimate goal of sustained viral suppression cannot be achieved without it.
Although determinants of HAART retention have been studied exhaustively [25, 26] , less is known about the process of HAART persistence, dropout, and reengagement over time. Episodes of HAART persistence and disengagement vary in length and the determinants of these episode durations may have critical implications for clinical practice and public health policy. Dynamic characterization, as afforded by advances in longitudinal data analysis [27] [28] [29] , can help to shed light on the longitudinal process (i.e. pattern of HAART persistence and disengagement) in the interest of informing clinical practice. This form of analysis may also provide important information to capture within mathematical models used to estimate transmission dynamics and make resource allocation decisions.
We aimed to identify and characterize possible determinants of successive durations of HAART retention and nonretention over time. We applied Cox proportional hazards frailty models to link health administrative data captured for the population of PLHIV in British Columbia (BC) between 1996 and 2012 to address our objectives.
Methods

Study population
This study was based on a provincial-level linkage of seven health administrative databases and disease registries, including the BC Centre for Excellence in HIV/AIDS drug treatment program and virology registries [antiretroviral dispensations, plasma viral load (pVL), and CD4 þ cell tests]; the BC Centre for Disease Control HIV testing database (HIV diagnosis); the Medical Services Plan database (physician billing records); the discharge abstract database (hospitalizations); the BC PharmaNet database (nonantiretroviral drug dispensations); and the BC Vital Statistics database (deaths). Details regarding the construction of the population-level cohort and available databases have previously been described [30, 31] .
We considered all cohort members who accessed HAART between 1 July 1996 and 30 June 2012. As our interest was in characterizing the natural course of HAART retention, we excluded those with a documented structured treatment interruption. These interruptions were applied to a limited group of individuals between 2000 and 2005 in response to growing concerns regarding toxicity and development of resistance to antiretroviral medications. Use of these interruptions has since been discontinued [11] . We also excluded individuals who had previously accessed mono or duoantiretroviral therapy (ART) as their disease course, given that their experience with antiretroviral medication may differ substantially from those initiating treatment in the HAART era. Thus, individuals were naive to antiretrovirals at the point of HAART initiation. For each individual, detailed HAART dispensation data was available from the point of (within province) HAART initiation to death, administrative loss to follow-up, or censorship (ongoing care as of 30 June 2012). Administrative loss was defined as no health records in any of the linked databases for a period of at least 18 months.
The study cohort was followed in a unique environment characterized by universal free medical care, including inpatient and outpatient care, laboratory monitoring, and antiretroviral medications. PVL data capture in the BC Centre for Excellence registries are complete for the population of individuals with HIV/AIDS in the province, and CD4 þ cell count data capture has previously been estimated at 80% [26] . This study received approval from the University of British Columbia/Providence Healthcare Research Ethics Board.
Measures
The dependent variable in our analysis was the duration of episodes on and off HAART, according to administrative medication dispensation records. An episode of HAARTwas considered discontinued if individuals had a gap of at least 30 days between days in which medication was prescribed; thus, on and off-HAART episodes were mutually exclusive and exhaustive in the classification of follow-up from the time of HAART initiation. This threshold was chosen because of the relative speed of viral rebound among those discontinuing treatment. Studies to date have shown that in the era of contemporary HAART, treatment interruptions lasting as short as a few days can be associated with virologic failure [32, 33] . Parienti et al. [34] found that patients on a nonnucleoside reverse transcriptase inhibitor (NNRTI)based regimen have a 50% probability of virologic failure (400 copies/ml) after a 15-day treatment interruption, although this duration likely varies depending on the HIV treatment regimen [23] .
A range of covariates previously hypothesized to impact HAART retention were incorporated including patient demographics [age at episode initiation (<30, 30-39, 40-49, 50þ), sex, known aboriginal ethnicity, HIV risk group -known MSM, known history of injection drug use, or other], medical comorbidity (Charlson comorbidity index score [35] [36] [37] in the year prior to episode initiation), HIV disease history at episode initiation [time from diagnosis, CD4 þ cell count and pVL (undetectable vs. detectable), AIDS status], calendar year of HAART initiation (1996-1999, 2000-2003, 2004-2007, 2008-2012) , HAART treatment regimen at episode initiation (traditional regimens including zidovudine, lamivudine, didanosine, stavudine, nevirapine, abacavir, nelfinavir, and ritonavir; contemporary regimens including lamivudine þ tenofovir, emtricitabine þ tenofovir, tipranavir, maraviroc, raltegravir, etravirine, atazanavir, enfuvirtide, efavirenz, and ritonavir þ other protease inhibitor or boosted protease inhibitor-based regimens; multidrug resistance regimens including five or more drugs), and physician contact during 1 year prior to episode initiation (number of visits to general practitioner/specialist and visits related to HIV). We note that the threshold for pVL undetectability has decreased from 500 copies/ml in 1996, to 400 copies/ml in 1997, to 50 copies/ml in 1999 and 40 copies/ml in 2008 [4] . Finally, a set of variables were created to indicate the HAART/off-HAART episode count, (i.e. first, second, ..., 6th episode).
Statistical analysis
The determinants of the time to discontinuation of HAART and off-HAART episodes were analyzed using time-to-event data statistical techniques. Mantel-Haenszel tests were conducted for each independent variable considered in the analyses. The assumption of proportionality for each of the study variables was assessed by visual inspection of Schoenfeld residual plots and weighted residuals score tests [38] . Nonproportional hazards were accepted if the variation in b(t) was not large in comparison with the parameter estimate. The resulting parameter estimates were therefore time-averaged regression effects. Given the simple structure of the regression model (i.e., no random effects on covariates), nonproportionality of the covariates did not bias the estimates of the variance components [39] .
Proportional hazards g frailty models were fitted to account for the dependence in the length of individuals' repeated HAART episodes [28, 29] . The proportional hazards gamma frailty model can be expressed as h ij ðtÞ ¼ h 0 ðtÞv j expðb 0 Z ij Þ, wherein h 0 ðtÞ is the unspecified baseline hazard, Z ij is the fixed-effect covariate matrix for episode i ¼ 1; . . . ; n j among individuals j ¼ 1; . . . ; m; and b is a vector of regression coefficients. The unobserved random effect, or frailty, for the j th individual (v j ) was assumed to follow a gamma distribution (v j gð1=u; 1=uÞ). Frailties are unobservable random variables corresponding to each individual's underlying modification of the baseline hazard function. They represent unobserved covariates common across multiple treatment episodes for each individual. Furthermore, the proportional hazards g frailty model captures the correlation in episode lengths within an individual; conditional on the frailty terms, the episode lengths are independent [27] .
In addition, we executed a parallel proportional hazards frailty model on the 'gap times' between treatment discontinuation and reinitiation among those with at least one 30-day gap. In doing so, the aforementioned set of covariates was updated according to the date of HAART discontinuation (and thus 1 day prior to the start of the 'gap time' initiation). As a sensitivity analysis to determine whether patterns of the duration of successive HAART and off-HAART episodes was consistent over time, we included models in which the HAART and off-HAART episode count variable was interacted with the calendar year of HAART initiation. Analysis was executed using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina, USA), and R version 2.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Table 1 provides a description of the 6152 individuals included in the analysis, at the point of HAART initiation. Briefly, 81.2% were male, 40.6% were people who inject drugs (PWID), and 42.8% initiated treatment with a low (<200 cells/ml) CD4 þ cell count.
Durations of HAART and off-HAART episodes are described in Table 2 . In total, we observed 18 695 HAART and 13 975 off-HAART episodes. The median (25th, 75th percentile) duration of all HAART episodes was 6.8 months (2.3, 19.5), with 21.5% lasting at least 24 months. First episodes tended to last longer, a median 12.7 months (3.7, 35.8), with 34.9% lasting at least 2 years. Over 29% of the individuals included in the study were continuously retained on HAART from initiation of their first episode to the end of follow-up, whereas 29.8% had 12 or more distinct treatment episodes. In contrast, off-HAART episodes lasted a median 1.9 months (1.2, 4.5), with little difference across successive episodes (not adjusting for other covariates). Over 10% (12.0%) of individuals discontinuing their initial HAART episode never reentered treatment. Table 3 provides results of multiple Cox proportional hazards frailty regression models for on and off-HAART episodes. Controlling for other covariates, among individuals with multiple treatment attempts, successive HAART episodes tended to decrease in duration (i.e., greater adjusted hazard of episode discontinuation). Second episodes were 24% shorter than first episodes [adjusted hazard ratio: 1.24; 95% confidence interval (CI): (1.17, 1.31)], third episodes were 47% shorter than first episodes [1.47 (1.38, 1.57)], and sixth or more episodes were 76% shorter than first episodes [1.76 (1.63, 1.91)]. Younger age, a history of injection drug use, and First Nations ethnicity were all associated with shorter HAART episode durations. Those with higher CD4 þ cell counts or detectable pVL at episode initiation tended to have shorter treatment durations, whereas those initiating treatment with a contemporary treatment regimen tended to have longer treatment durations than those initiating with traditional or multidrug resistance regimens. Those with a high volume of general practitioner visits (>10 in the past 12 months) tended to have shorter subsequent HAART episodes, whereas those with regular specialist visits (>3 in the past 12 months) had longer treatment episodes. Finally, those initiating HAART in later years tended to have longer HAART episodes, controlling for other factors. In particular, those initiating treatment in 2008-2012 remained in treatment 27% longer than those initiating in 1996-1999 [0.73 (0.67, 0.80)].
In contrast, successive off-HAART episodes were similar in duration from first episodes after controlling for relevant covariates and adjusting for intraindividual correlation, although fourth and fifth episodes tended to be 12-13% shorter in duration. Older age was associated with shorter off-HAART episodes, heterosexuals tended to have shorter off-HAART episodes compared with individuals with other HIV risk behaviors, whereas those with a prior AIDS diagnosis had substantially shorter off-HAART episodes [1.55 (1.46, 1.64)] than others. Those initiating HAART in more recent years had substantially shorter off-HAART episodes, compared with those initiating in 1996-1999 [2004-2007: 1. 26 (1.18, 1.36); 2008-2012: 1.59 (1.47, 1.71)].
We explored the temporal relationship of successive on and off-HAART episode durations further by testing the interaction between the constructed episode count variable and the temporal phase of the episode initiation. Results (shown in Fig. 1 ) indicate that the pattern of decreasing durations of on-HAARTepisodes is consistent across temporal phases of HAART initiation, with successively wider CIs in later phases likely because of smaller cell sizes for later episodes. Off-HAART episodes again showed no distinct pattern in terms of durations of successive episodes across temporal phases. Although off-HAART episodes tended to increase in duration among 2008-2012 HAART initiators, CIs were exceptionally wide and results were not statistically significant. CCI, Charlson comorbidity index; GP, general practitioner; PWID, people who inject drugs -indication of history of injection drug use.
Discussion
Our results demonstrate a substantial level of treatment dropout and reinitiation, or 'churn', among individuals on HAART in a high-resource setting with universal access to treatment and routine HIV care. Successive HAARTepisodes tended to decrease in duration, whereas off-HAART episodes remained relatively constant. Nonetheless, the duration of HAART episodes was greater for individuals initiating HAART in later years, whereas off-HAARTepisodes were shorter. In particular, durations of HAART episodes for those initiating treatment after 2008 were 27% longer than those initiating between 1996 and 1999, whereas off-HAART episodes were 59% shorter.
The observed increasing durations of HAART episodes (and diminishing durations of off-HAART episodes) in more recent years (2008-2012) is encouraging, and corroborates previously reported findings of improving treatment outcomes, in terms of both disease progression [40] and mortality outcomes [41, 42] . This is likely largely attributable to improvements in the treatment regimens themselves, with reduced pill burdens and improved safety and tolerability profiles boosting treatment adherence.
It should come as no surprise that more frequent contact with medical specialists and receipt of HIV care was associated with both longer HAARTepisodes and shorter off-HAART episodes. The challenge remains maintaining consistent contact with the patient population at greatest risk of poor HAART persistence. These included individuals of younger age, female sex, aboriginal ethnicity, and a history of injection drug use; each of these factors was associated with both decreased treatment persistence (i.e., shorter durations on therapy) and longer treatment interruptions. These characteristics are consistent with the previous study findings [14, 23] . In particular, we found that PWID experienced a high degree of churn. This finding may be partly explained by multiple competing priorities that PWID may face including multiple substance use disorders, mental health issues, as well as food and housing insecurity [37, 38] . Although we did not have socioeconomic or mental health data to provide greater context, results from the study by Ing et al. [43] on HAART persistence among PWID showed that nonpersistence of at least 7 days was highly associated with high addiction severity (adjusted odds ratio ¼ 17.4) and high depressive symptoms (adjusted odds ratio ¼ 5.0). As such, concurrent harm reduction, mental health, and HAART support is likely vital to ensure that PWID are consistently retained on HAART.
Decreasing durations of successive HAART episodes and relatively stable durations of off-HAARTepisodes call for
Cascade churn in HAART retention Nosyk et al. 1685 targeted interventions for those with intermittent HAART retention. This is of concern as decreased persistence (i.e. shorter durations on therapy) is associated with virological failure, HIV drug resistance emergence, and increased mortality [9, 23, 44] . Understanding both treatment persistence and the frequency and duration of on-HAART episodes has become increasingly important with the advent of contemporary HAART, as studies suggest that a higher frequency and shorter durations of treatment may be a greater predictor of virologic failure among those on NNRTI-based regimens but not on protease inhibitorbased regimens [33, 34, 45] . This is likely attributable to the lower genetic barrier of NNRTI-based regimens [46] . In a preliminary analysis within our database for individuals with pVL measurements available both 90 days before and after treatment discontinuation (25.1% of all discontinued episodes), 38.3% of individuals previously virally suppressed experienced viral rebound (results not shown) -a conservative figure given the extent of missing data. Further study, accounting for intermitted patterns of treatment and HAART regimen switching, is required to fully demonstrate the long-term health consequences of HAART interruptions and intermittent HAART retention.
Another important and timely finding was that individuals initiating at high CD4 þ cell counts (200 cells/ml) were more likely to have shorter on-treatment HAART episode durations than those starting at less than 200 cells/ ml. AIDS status was similarly associated with longer HAART durations and shorter off-HAART episodes. Similar findings have been observed elsewhere [14, 22, 47, 48] . Although our results suggested better retention among HAART initiators in more recent years regardless of CD4 þ cell count, individuals are now increasingly initiating ART at high CD4 þ cell counts because of relaxed HAART initiation guidelines [49, 50] , making monitoring of retention outcomes an increasingly critical priority. Given the growing number of treatment as prevention programs being implemented worldwide, long-term evidence-based treatment persistence support programs are necessary to minimize treatment interruptions. There is at present a paucity of research on HAART retention and reengagement among those discontinuing treatment. As noted, this is of particular importance among PWID, as well as younger individuals at earlier stages of disease progression. Interventions found to be successful to date include the use of mobile phones to act as appointment and pill reminders [51] . Improving this aspect of the cascade of HIV care is the subject of considerable focus locally and should be prioritized internationally to fully capitalize on both the individual and public health benefits of HAART.
Our analysis had several limitations. First, the study was conducted in a setting characterized by free HIV treatment, including antiretroviral medications. As such, it may be considered a 'best-case scenario', particularly among PWID, which comprises the majority of those with periods of treatment nonretention. Second, HAART durations relied on prescription refill data and were thus measured with a degree of error. Although administrative loss to follow-up was considered, it is possible, although unlikely, that individuals may have received ART dispensations out of province during periods considered off treatment. Finally, given the observational nature of the study, there is always potential for unmeasured confounding. In our case, patient-specific motivational factors and attitudes toward ART may have influenced results, however, overall patterns of HAART persistence represented that of the population of PLHIV in BC, excluding those initiating antiretroviral treatment before the HAARTera or having a structured treatment interruption.
In conclusion, we found extensive evidence of churn among those on HAART in a setting with universal access to treatment and care. Incorporating monitoring Fig. 1 . Adjusted hazards of time to HAART and off-HAART episode discontinuation. Hazard ratios were estimated by including interaction terms between (multinomial) episode count and temporal era variables in a multiple regression model, controlling for all covariates noted in Table 3 . 95% CI, 95% confidence interval; epi, episode.
of HAART churn as a part of routine HIV care surveillance is crucial to effective HIV care intervention planning. Furthermore, although HAART retention improved over time, there remains an urgent need to develop clinical strategies and public health policies to improve HAART persistence, particularly among those at earlier stages of disease progression, the young, and PWID.
